Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Arqit Quantum Inc (ARQQ) vs Medpace Holdings Inc (MEDP) Price & Performance

Arqit Quantum IncTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

Arqit Quantum Inc vs Medpace Holdings Inc — how do they compare? Arqit Quantum Inc trades at $23.52 (market cap $424.79M), while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: Medpace Holdings Inc is far larger — about 39.8× Arqit Quantum Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Arqit Quantum Inc nearer its low. Which is the better fit depends on your goals.

ARQQMEDP
Market Cap
$424.79M$16.90B
Sector
TechnologyTechnology
52-Week High
$58.27$620.59
52-Week Low
$11.78$393.42
Enterprise Value
$398.10M$16.52B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Arqit Quantum Inc

ARQQ trades at $23.72, up 4.91% today, with a bullish technical signal from moving averages despite overbought RSI readings. The company shows explosive revenue growth but deep losses, with a P/S ratio of 352.9 reflecting high growth expectations. Recent news highlights a proof-of-concept with nLighten and strong H1 2026 revenue growth of 829% year-over-year, signaling commercial traction in quantum-safe encryption.

Outlook hinges on scaling revenue to offset high costs, with analyst sentiment split evenly between Buy and Hold. Key risks include sustained cash burn and competitive pressure, but government and telecom deals offer upside if execution improves.

Medpace Holdings Inc

MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.

MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Arqit Quantum Inc

Arqit Quantum provides advanced cybersecurity software that uses symmetric key agreement technology. Its solutions protect networked devices and data against current and future cyber threats, including quantum attacks.

Read more on ARQQ

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP